MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment

被引：0
|
作者：
Xiaoyue Xu
Shaorong Yu
Wenbo Sun
Xiaobing Qin
Yan Chen
Leilei Zhou
Rui Lou
Shuchen Dong
Bo Shen
Jianzhong Wu
Jialan Zang
Haixia Cao
Meiqi Shi
Qin Zhang
Jifeng Feng
机构：
[1] Jiangsu Institute of Cancer Research,Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital
[2] Nanjing Medical University Affiliated Brain Hospital,Department of Neurosurgery
[3] Xuzhou First People’s Hospital,Department of Oncology, Huai’an First People’s Hospital
[4] Nanjing Medical University,Department of Oncology
[5] The First Hospital of Harbin City,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2018年 / 144卷
关键词：
Lung adenocarcinoma; MiRNA; Platinum resistance; Prediction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：431 / 438
页数：7
相关论文
共 50 条
  • [1] MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment
    Xu, Xiaoyue
    Yu, Shaorong
    Sun, Wenbo
    Qin, Xiaobing
    Chen, Yan
    Zhou, Leilei
    Lou, Rui
    Dong, Shuchen
    Shen, Bo
    Wu, Jianzhong
    Zang, Jialan
    Cao, Haixia
    Shi, Meiqi
    Zhang, Qin
    Feng, Jifeng
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (03) : 431 - 438
  • [2] An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy
    Qi, Lishuang
    Li, Yang
    Qin, Yuan
    Shi, Gengen
    Li, Tianhao
    Wang, Jiasheng
    Chen, Libin
    Gu, Yunyan
    Zhao, Wenyuan
    Guo, Zheng
    BRITISH JOURNAL OF CANCER, 2016, 115 (12) : 1513 - 1519
  • [3] An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy
    Lishuang Qi
    Yang Li
    Yuan Qin
    Gengen Shi
    Tianhao Li
    Jiasheng Wang
    Libin Chen
    Yunyan Gu
    Wenyuan Zhao
    Zheng Guo
    British Journal of Cancer, 2016, 115 : 1513 - 1519
  • [4] PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy
    Yang, Yang
    Xu, Wen
    Liu, Di
    Ding, Xi
    Su, Bo
    Sun, Yifeng
    Gao, Wen
    TUMOR BIOLOGY, 2016, 37 (06) : 7785 - 7796
  • [5] Functional miRNA variants affect lung cancer susceptibility and platinum-based chemotherapy response
    Fang, Chao
    Li, Xiang-Ping
    Chen, Yi-Xin
    Wu, Na-Yiyuan
    Yin, Ji-Ye
    Zhang, Wei
    Zhou, Hong-Hao
    Liu, Zhao-Qian
    JOURNAL OF THORACIC DISEASE, 2018, 10 (06) : 3329 - 3340
  • [6] COMPARISON OF GEFITINIB AND PLATINUM-BASED CHEMOTHERAPY AND ONLY PLATINUM-BASED CHEMOTHERAPY TO TREAT LUNG ADENOCARCINOMA
    Yang, L.
    Fan, J. H.
    Liu, L. L.
    Su, Y.
    Lu, D.
    Huang, J. Y.
    Zhang, H.
    Li, Y.
    Huo, H. D.
    Du, Z. H.
    Liu, G. T.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2018, 32 (03): : 613 - 618
  • [7] Development of a miRNA-seq based prognostic signature in lung adenocarcinoma
    Chathura Siriwardhana
    Vedbar S. Khadka
    John J. Chen
    Youping Deng
    BMC Cancer, 19
  • [8] Development of a miRNA-seq based prognostic signature in lung adenocarcinoma
    Siriwardhana, Chathura
    Khadka, Vedbar S.
    Chen, John J.
    Deng, Youping
    BMC CANCER, 2019, 19 (1)
  • [9] Identification of a 7-miRNA signature for predicting the prognosis of patients with lung adenocarcinoma
    Liu, Ruijun
    Guo, Zhiyi
    Huang, Jia
    Li, Jiantao
    Tan, Qiang
    Luo, Qingquan
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2022, 247 (08) : 641 - 657
  • [10] Four-miRNA signature as a prognostic tool for lung adenocarcinoma
    Lin, Yan
    Lv, Yufeng
    Liang, Rong
    Yuan, Chunling
    Zhang, Jinyan
    He, Dan
    Zheng, Xiaowen
    Zhang, Jianfeng
    ONCOTARGETS AND THERAPY, 2018, 11 : 29 - 36
12345